Antiobesity efficacy of a novel cannabinoid - 1 receptor
inverse agonist, N --LSB-(1S, 2 S)-3 -(4 - chlorophenyl)-2 -(3 - cyanophenyl)-1-methylpropyl]-2-methyl-2 --LSB-[5 -(trifluoromethyl) pyridin -2-yl] oxy] propanamide (MK - 0364), in rodents.
We report the crystal structure of a human β2 - adrenergic receptor — T4 lysozyme fusion protein bound to the partial
inverse agonist carazolol at 2.4 angstrom resolution.
Following postdoctoral training at the State University of New York, Stony Brook with Masayori Inouye, he joined the Schering - Plough Department of Immunology, where he characterized the biology of a new class of cannabinoid CB2 receptor - specific
inverse agonists.